CLOVIS ONCOLOGY INC
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth. The year 2013 was very encouraging for small cap biotech companies. The growth prospects of these companies were way more than the pharmaceutical giants, which is why investors trusted these companies with their cash. I saw a number of biotech stocks experience rapid escalation in their more »
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe a couple of these stocks? Maybe you are considering an investment? Well, let's take a look at the top 5 biotech performers, and determine whether larger gains will be realized.
No. 5: Cancer Stock on the Move
Editor's Note: This article has been modified to correct the spelling of Soliris.
The healthcare industry is slowly becoming what the pre-crash technology industry was of the early 2000's. The emergence of new technologies in medicine, an aging working population, and retiring baby boomers are all expected to provide tremendous growth to the industry over the next several decades.
Many companies will inevitably capitalize on this growth more »
Every year, there is a big event for pharmaceutical companies known as ASCO. ASCO is the American Society Of Clinical Oncology, in which pharmaceutical companies post results on cancer trials. There were many companies that posted amazing results this time, but here, I will highlight three of them which will might be good for your portfolio in the long-term. The three pharmaceutical stocks to own for the long run are more »
Late last year, Clovis Oncology (NASDAQ: CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy. The company said it was shutting down the development of the trial and was going to focus on its pipeline.
Now, Clovis Oncology is trading near $73 with gains of more than 100%. The gains followed exceptional data more »
In this concluding part of our study of Clovis Oncology (NASDAQ: CLVS), we will perform a valuation of the company based on the P/E multiple valuation method. In part 1, we analyzed the investment thesis behind Clovis, and in part 2, we detailed its product pipeline and cash position. I urge you to read both parts to understand what follows better.
Stock Valuation of Clovis Oncology
We believe the more »
In Part I of this article, I discussed the basic investment thesis of Clovis Oncology (NASDAQ: CLVS). In this part, I will discuss the company's product pipeline and cash position, and conclude with a valuation in the third part. I suggest serious investors read each part to get a thorough understanding of this interesting company.
Product Pipeline of Clovis:
CO-1686 is an orally available, small molecule epidermal growth more »
NOTE: This is an exhaustive study of Clovis Oncology , and as such, I have broken it up into 3 parts. Part 1 will deal with pros and cons of investing in the company, part 2 will outline the product pipeline and the company's cash position, and the last part will do a valuation of the company using the P/E multiple valuation method. If you want a thorough grounding more »
Celgene (NASDAQ: CELG) is a global biopharmaceutical company focused on treating cancer and immune-inflammatory related diseases. The Summit, New Jersey-based company was founded in 1986 and has grown to employ more than 4,500 people worldwide.
Let’s evaluate Celgene’s business as it stands today before considering upcoming catalysts for the company in the next six to twelve months. With a market capitalization of approximately $33 billion, Celgene derives more »